v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities:    
Net income (loss) $ 19,167,678 $ (9,798,083)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Gain on bargain purchase (21,928,500)
Net loss on asset disposals of discontinued operations 3,677,500
Gain on disposition of business (100)
Gain on disposition of asset retirement obligations (2,444)
Gain on sale of fixed assets (1,085)
Fair value of vested stock options 311,480 65,460
Goodwill impairment of discontinued operations 751,421
Fixed asset impairment 878,269 738,913
Depreciation of property and equipment 78,383 89,947
Depreciation of discontinued operations 91,908 1,779,050
Amortization of long-term intangible assets 1,098,737
Accretion of asset retirement obligations 1,912,968
Changes in operating assets and liabilities:    
Accounts receivable (390,188)
Accounts receivable from discontinued operations 3,970,553
Unbilled receivables from discontinued operations 22,813 5,788
Contract assets from discontinued operations 154,354 92,956
Prepaid expenses and other current assets 13,913 86,601
Accounts payable 580,345 (3,378,895)
Accounts payable from discontinued operations (221,442) 221,442
Accrued expenses (113,696) 60,549
Accrued expenses from discontinued operations (35,496) 35,496
Cash paid for asset retirement obligations (1,479,574)
Deposits (15,395) 1,442
Deposits from discontinued operations 8,534
Net cash provided by (used in) operating activities 123,028 (1,591,426)
Cash flows from investing activities:    
Cash paid for equipment purchases (100,000)
Proceeds from asset sales 492,000
Long-term deposits received 1,000,000
Net proceeds from sale of assets from discontinued operations 270,000
Net insurance proceeds from casualty loss from discontinued operations 160,000
Net proceeds from disposition of Graphium Biosciences 100
Net cash provided by investing activities 1,392,000 430,100
Cash provided by financing activities:    
Issuance of shares for cash 1,150,000 1,000,000
Repayment of long-term debt (522,143) (1,448,188)
Repayment of line of credit (200,000) (400,000)
Net cash provided by/ (used in) financing activities 427,857 (848,188)
Net increase (decrease) in cash and cash equivalents 1,942,885 (2,009,514)
Cash and cash equivalents - beginning of period 167,286 2,176,800
Cash and cash equivalents - end of period 2,110,171 167,286
Cash paid during the period for:    
Interest expense 170,579 486,515
Income taxes 77,368
Supplemental schedule of non-cash investing and financing activities:    
Line of credit converted to term bank debt 1,800,000
Reduction in accounts receivable as part of FOLA transaction 2,958,516
Acquisition of land related to asset retirement obligation 41,359,505
Debt forgiveness related to equipment surrender 1,012,375
Debt forgiveness related to Collins Building asset disposal 2,940,836
Debt reduction transferred to deficiency claim 2,082,277
Initial recording of asset retirement cost and asset retirement obligation 79,701,104
Reduction of bargain purchase gain for noncontrolling equity interest $ 16,326,016